Speciality Medicines IPO
Speciality Medicines IPO Details
-
Open Date
20 Mar 2026
-
Close Date
24 Mar 2026
-
Listing Date
30 Mar 2026
- IPO Price Range
₹ 117 to ₹124
- IPO Size
₹ 29.14 Cr
- Listing Exchange
BSE SME
Speciality Medicines IPO Timeline
Last Updated: 19 March 2026 5:14 AM by 5paisa
Speciality Medicines Limited is a Mumbai-headquartered, GDP-certified pharmaceutical wholesaler, distributor, and exporter, incorporated in February 2021. A global supplier of high-quality pharmaceutical products, the company delivers specialty medications that address changing global healthcare needs, adhering to the highest industry standards through rigorous testing and strict compliance with international health regulations. SML has access to supply super-specialty medicines used in the treatment of cancer, HIV/AIDS, blood disorders, and kidney problems. All supplied products are sourced from WHO-GMP-certified manufacturers or their authorised distributors, ensuring safety, efficacy, and competitive pricing.
Established in: 2021
Managing Director: Parth Goyani
Speciality Medicines IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹29.14 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹29.14 Cr |
Speciality Medicines IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | 2,34,000 |
| Retail (Max) | 2 | 2,000 | 2,48,000 |
| S - HNI (Min) | 3 | 3,000 | 3,51,000 |
| S - HNI (Max) | 8 | 8,000 | 9,92,000 |
| B - HNI (Min) | 9 | 9,000 | 11,16,000 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Revenue | 23.18 | 27.52 | 58.27 |
| EBITDA | 3.58 | 5.26 | 9.09 |
| PAT | 1.7 | 2.93 | 8.61 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Total Assets | 13.26 | 22.68 | 39.98 |
| Share Capital | 3.82 | 5.12 | 6.44 |
| Total Liabilities | 13.26 | 22.68 | 39.98 |
| Cash Flows (₹ Crores) | FY23 | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | -3.65 | -4.80 | -5.8 |
| Net Cash Generated From / (used in) Investing Activities | -0.12 | -0.03 | -2.07 |
| Net Cash Generated From / (used in) Financing Activities | 3.88 | 4.81 | 8.46 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 0.10 | -0.01 | 0.6 |
Strengths
1. Operates in super-specialty segments — oncology, HIV/AIDS, blood disorders, and nephrology
2. Sources exclusively from WHO-GMP certified manufacturers or authorised distributors
3. Holds ISO 9001:2015 and GDP certifications
4. Promoter-led, founder-driven management with hands-on operational oversight
Weakness
1. Incorporated only in February 2021 - short operating history in a compliance-heavy sector
2. Converted to public limited company as recently as June 2024
3. Financial statements cover limited periods, restricting long-term performance visibility
4. No owned manufacturing; fully dependent on third-party supply chains
Opportunities
1. Rising incidence of cancer, kidney disease, and HIV drives sustained demand
2. Planned R&D centre signals intent to build proprietary capabilities
3. Export orientation opens access to underserved markets in Africa, Southeast Asia, and the Middle East
4. Government focus on life-saving medicine access creates favourable policy tailwinds
Threats
1. Highly regulated environment - any compliance lapse could disrupt operations
2. Concentrated supplier base creates supply chain vulnerability
3. Competition from established distributors and multinationals with deeper capital
4. Currency fluctuations can impact pricing and availability of imported medicines
1. Operates in high-demand super-specialty segments — oncology, HIV/AIDS, blood disorders, and nephrology
2. Sources from WHO-GMP certified manufacturers, ensuring quality and regulatory compliance
3. Export-oriented model with access to underserved global markets
4. Planned R&D centre signals long-term capability building and growth ambition
Speciality Medicines Limited is entering the public markets via a fresh issue of up to 23,50,000 equity shares on the BSE SME platform. Operating in high-demand therapeutic segments - oncology, HIV/AIDS, blood disorders, and nephrology — the company is well-positioned to capitalise on India's growing specialty pharma market. With a planned R&D centre, WHO-GMP compliant sourcing, and an export-oriented model, SML's growth trajectory is anchored in rising disease burden, expanding global healthcare access, and increasing demand for life-saving medicines.
- Companies
- Type
- Opening On
-
Central Mine Planning & Design Institute
- Mainboard
-
20th Mar
- Pre-Book
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Speciality Medicines IPO opens from March 20, 2026 to March 24, 2026.
The size of Speciality Medicines IPO is ₹29.14 Cr.
The price band of Speciality Medicines IPO is fixed at ₹117 to ₹124 per share.
To apply for Speciality Medicines IPO, follow the steps given below:
● Login to your 5paisa demat account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Speciality Medicines IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Speciality Medicines IPO is of 2,000 shares and the investment required is ₹2,34,000.
The share allotment date of Speciality Medicines IPO is March 25, 2026
The Speciality Medicines IPO will likely be listed on March 30, 2026.
Unistone is the book running lead manager for Speciality Medicines IPO.
Speciality Medicines IPO plans to utilise the raised capital from the IPO for:
1. Setting up of Research and Development (R&D) center (₹12.68 Cr)
2. Product registration and development in the international markets (₹3 Cr)
3. Funding for marketing and brand promotion activities promotional activities (₹1.66 Cr)
4. To meet working capital requirements (₹8 Cr)
5. General Corporate Purposes